Auro Pharma, a subsidiary of Aurobindo Pharma, will acquire the non-oncology prescription formulations business of Khandelwal Laboratories on a going-concern, slump-sale basis for a cash consideration of ₹325 crore, subject to working capital true-up as per the definitive agreements, Aurobindo Pharma said in a filing on Thursday.
The acquired business comprises 23 brands marketed across 67 SKUs and nine pipeline products, with anti-infective and pain management as its major portfolios. It reported turnover of ₹113.5 crore in 2024-25 and an EBITDA of ₹28.9 crore.
The business includes a field force of about 470 and more than 1,600 stockists and distribution-related infrastructure. The acquisition, effective January 1, 2026, is expected to add brands in pain management and anti-infective, complement Auro Pharma’s existing product portfolios and support expansion in the domestic market.
Leave a Reply